MP02-15 IMPACT OF MV140 ON PATIENT RELATED BURDEN OF DISEASE ASSOCIATED WITH THE MANAGEMENT OF RECURRENT URINARY TRACT INFECTIONS (RUTI)

Abstract

You have accessJournal of UrologyCME1 May 2022MP02-15 IMPACT OF MV140 ON PATIENT RELATED BURDEN OF DISEASE ASSOCIATED WITH THE MANAGEMENT OF RECURRENT URINARY TRACT INFECTIONS (RUTI) J. Curtis Nickel, Stephen Foley, Miguel Casanovas, Raquel Caballero, and María Fernanda Lorenzo-Gómez J. Curtis NickelJ. Curtis Nickel More articles by this author , Stephen FoleyStephen Foley More articles by this author , Miguel CasanovasMiguel Casanovas More articles by this author , Raquel CaballeroRaquel Caballero More articles by this author , and María Fernanda Lorenzo-GómezMaría Fernanda Lorenzo-Gómez More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002514.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Women with rUTI suffer from episodic pain and urinary symptoms, disability, costs, poor quality of life, as well as short- and long-term complications of antibiotic therapy. A randomized placebo-controlled trial evaluating a polybacterial sublingual vaccine, MV140, presented as a late breaking AUA abstract in September 2021 showed efficacy and safety in reducing the risk of developing UTI in women with rUTI (ITT n= 215). The personal impact of this vaccine on burden of disease in the women enrolled in this study was evaluated. METHODS: Female subjects with rUTI were randomized to placebo for 6 months or vaccine for 3 or 6 months (1:1:1 ratio) and followed for 12 months from initiation of therapy. The primary endpoint and major secondary endpoint were the mean number of UTI and UTI free rate in the 9-month efficacy period following 3 months of intervention. Secondary analyses relevant to this analysis included impact on patient safety, symptom severity, antibiotic use, healthcare utilization, costs and quality of life. RESULTS: As previously reported, there was a significant reduction in UTI episodes (3.0 in placebo group [IQR, 0.5-6.0] compared to 0.0 [IQR, 0.0-1.0] in both groups receiving MV140 [P<0.001]) and UTI-free rate (25.0% in placebo, 55.7% in MV140 3M and 58.0% in MV140 6M groups; P<0.001) with few treatment-related adverse events in all groups (study total n=9). The median number of antibiotic prescriptions was 4.5 [IQR, 1.0-8.5] for placebo group compared to 1.0 [IQR, 0.0-3.0] in both groups receiving MV140 (P<0.001). A significant reduction (75.0-100.0% decrease) in the need for healthcare resources with similar reduction in healthcare costs were observed in the vaccinated subjects. UTI symptom severity was significantly reduced in the vaccinated groups with a concomitant improvement in quality of life experienced by the vaccinated subjects compared to those receiving placebo (Figure 1). CONCLUSIONS: MV140 significantly reduces the personal burden of UTI disease by safely decreasing risk of subsequent UTI, reducing severity of breakthrough UTI, reducing antibiotic use, healthcare resources, costs and ultimately improving the quality of life in women suffering from rUTI. Source of Funding: Inmunotek © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e16 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information J. Curtis Nickel More articles by this author Stephen Foley More articles by this author Miguel Casanovas More articles by this author Raquel Caballero More articles by this author María Fernanda Lorenzo-Gómez More articles by this author Expand All Advertisement PDF DownloadLoading ...